| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1047638614 |
| P356 | DOI | 10.1007/S12325-016-0315-8 |
| P932 | PMC publication ID | 4846687 |
| P698 | PubMed publication ID | 26984315 |
| P5875 | ResearchGate publication ID | 298798361 |
| P2093 | author name string | Timothy L Comstock | |
| Megan E Cavet | |||
| John D Sheppard | |||
| P2860 | cites work | Dry eye: an inflammatory ocular disease | Q26852044 |
| Treatment of ocular inflammatory conditions with loteprednol etabonate | Q28267087 | ||
| Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate | Q28268967 | ||
| Antiinflammatory action of glucocorticoids--new mechanisms for old drugs | Q28278037 | ||
| Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1 | Q28288989 | ||
| Intraocular pressure response to corticosteroids in children | Q33651935 | ||
| Iatrogenic glaucoma secondary to medications | Q33752399 | ||
| Corticosteroids and glaucoma risk | Q33821262 | ||
| The core mechanism of dry eye disease is inflammation | Q34510429 | ||
| Locally administered ocular corticosteroids: benefits and risks | Q34512886 | ||
| Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery | Q34606700 | ||
| The central role of conjunctival mast cells in the pathogenesis of ocular allergy | Q34666591 | ||
| An update on the surgical management of pterygium and the role of loteprednol etabonate ointment | Q35195192 | ||
| Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome | Q35529254 | ||
| Corneal Confocal Microscopy in Dry Eye Treated with Corticosteroids. | Q35613478 | ||
| Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis | Q35628440 | ||
| A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery | Q35853498 | ||
| Corticosteroid-induced glaucoma: a review of the literature | Q36118249 | ||
| Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial | Q36145683 | ||
| Corticosteroid effects on cell signalling | Q36384321 | ||
| Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. | Q36440361 | ||
| Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle | Q37157412 | ||
| Steroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophy | Q37539662 | ||
| Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis | Q37780934 | ||
| Risk factors for steroid response among cataract patients | Q37855155 | ||
| Steroid-induced iatrogenic glaucoma | Q37901293 | ||
| Use of loteprednol for routine prophylaxis after photorefractive keratectomy | Q38008645 | ||
| Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. | Q38019465 | ||
| Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? | Q38241140 | ||
| Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial | Q38410786 | ||
| Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese pat | Q38470946 | ||
| Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. | Q39203016 | ||
| Corticosteroid-induced glaucoma | Q39407547 | ||
| Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects | Q40297836 | ||
| Designing safer ophthalmic drugs by soft drug approaches. | Q40623396 | ||
| Design of novel soft corticosteroids | Q40810168 | ||
| Marked intraocular pressure response to instillation of corticosteroids in children | Q42006190 | ||
| A Prospective, Open-label Study to Compare the Efficacy and the Safety of Topical Loteprednol Etabonate and Topical Flurbiprofen Sodium in Patients with Post-Operative Inflammation after Cataract Extraction | Q42102961 | ||
| Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate | Q42103396 | ||
| Ocular-hypertensive response to topical steroids in children | Q42546045 | ||
| Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop | Q43245437 | ||
| Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation | Q43273343 | ||
| Comparison of in Vitro Potency of Corticosteroids with Ability to Raise Intraocular Pressure | Q43413695 | ||
| Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study | Q43845738 | ||
| Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery | Q43939243 | ||
| Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model | Q44063509 | ||
| Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery | Q44650962 | ||
| Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease | Q44961509 | ||
| A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance | Q45056544 | ||
| Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers | Q46774904 | ||
| Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis | Q46863613 | ||
| Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation. | Q50437146 | ||
| Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report. | Q50537908 | ||
| INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS | Q53035132 | ||
| A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. | Q53647473 | ||
| Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes | Q68070243 | ||
| Intraocular pressure response to loteprednol etabonate in known steroid responders | Q72866271 | ||
| A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis | Q72992644 | ||
| A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I | Q73281048 | ||
| A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group | Q74424008 | ||
| Change in intraocular pressure during long-term use of loteprednol etabonate | Q77131509 | ||
| A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis | Q77178448 | ||
| A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2 | Q77352461 | ||
| Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group | Q77766048 | ||
| A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis | Q78022192 | ||
| STATISTICAL ATTRIBUTES OF THE STEROID HYPERTENSIVE RESPONSE IN THE CLINICALLY NORMAL EYE. I. THE DEMONSTRATION OF THREE LEVELS OF RESPONSE | Q78321240 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis | Q80384688 | ||
| Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone | Q80978992 | ||
| A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis | Q83273881 | ||
| Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety | Q84203367 | ||
| Visual loss caused by corticosteroid-induced glaucoma: how to avoid it | Q84522170 | ||
| Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial | Q87590357 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polycyclic compound | Q426145 |
| eye disease | Q3041498 | ||
| ocular hypertension | Q9294051 | ||
| P304 | page(s) | 532-52 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure | |
| P478 | volume | 33 |
| Q50331769 | A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty. |
| Q55503819 | Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery. |
| Q48336618 | Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation. |
| Q37608776 | Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery |
| Q90403137 | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| Q64982759 | Cucurbita argyrosperma Seed Extracts Attenuate Angiogenesis in a Corneal Chemical Burn Model. |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q88086011 | Early results on the use of chitosan-N-acetylcysteine (Lacrimera®) in the management of dry eye disease of varied etiology |
| Q90331855 | Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery |
| Q92855870 | Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies |
| Q99588884 | Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement |
| Q92603643 | Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery |
| Q64904107 | Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38. |
| Q60930956 | Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery |
| Q48344821 | The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. |
Search more.